Comparison of clinical pharmacology of voriconazole and posaconazole

Despite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a que...

Full description

Bibliographic Details
Main Authors: Beata M. Sienkiewicz, Łukasz Łapiński, Anna Wiela-Hojeńska
Format: Article
Language:English
Published: Termedia Publishing House 2016-12-01
Series:Contemporary Oncology
Subjects:
Online Access:https://www.termedia.pl/Comparison-of-clinical-pharmacology-of-voriconazole-and-posaconazole,3,28897,1,1.html
id doaj-c7ce4e251ba8489680f50bc2951fdb09
record_format Article
spelling doaj-c7ce4e251ba8489680f50bc2951fdb092020-11-24T22:38:08ZengTermedia Publishing HouseContemporary Oncology1428-25261897-43092016-12-0120536537310.5114/wo.2016.6459428897Comparison of clinical pharmacology of voriconazole and posaconazoleBeata M. SienkiewiczŁukasz ŁapińskiAnna Wiela-HojeńskaDespite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a quest for new antifungal drugs as well as for optimization of pharmacotherapy with already registered pharmaceutics. Voriconazole and posaconazole are broad-spectrum, new generation, triazole antifungal agents. The drugs are used in the pharmacotherapy of invasive aspergillosis, Candida and Fusarium infections. Voriconazole is also used in infections caused by Scedosporium . Posaconazole is used in the treatment of coccidioidomycosis and chromoblastomycosis. Besides some similarities, the two mentioned drugs also show differences in therapeutic indications, pharmacokinetics (mainly absorption and metabolism), frequency and severity of adverse drug reactions, drug–drug interactions and dosage. As both of the drugs are used in the treatment of invasive fungal infections in adults and children, detailed knowledge of the clinical pharmacology of antifungal agents is the main factor in pharmacotherapy optimization in treatment of fungal infections. The goal of the article is to present and compare the clinical pharmacology of voriconazole and posaconazole as well as to point out the indications and contraindications of using the drugs, determine factors influencing their pharmacotherapy, and provide information that might be helpful in the treatment of fungal infections.https://www.termedia.pl/Comparison-of-clinical-pharmacology-of-voriconazole-and-posaconazole,3,28897,1,1.htmlvoriconazole posaconazole clinical pharmacology cytochrome P-450 enzyme system drug monitoring
collection DOAJ
language English
format Article
sources DOAJ
author Beata M. Sienkiewicz
Łukasz Łapiński
Anna Wiela-Hojeńska
spellingShingle Beata M. Sienkiewicz
Łukasz Łapiński
Anna Wiela-Hojeńska
Comparison of clinical pharmacology of voriconazole and posaconazole
Contemporary Oncology
voriconazole
posaconazole
clinical pharmacology
cytochrome P-450 enzyme system
drug monitoring
author_facet Beata M. Sienkiewicz
Łukasz Łapiński
Anna Wiela-Hojeńska
author_sort Beata M. Sienkiewicz
title Comparison of clinical pharmacology of voriconazole and posaconazole
title_short Comparison of clinical pharmacology of voriconazole and posaconazole
title_full Comparison of clinical pharmacology of voriconazole and posaconazole
title_fullStr Comparison of clinical pharmacology of voriconazole and posaconazole
title_full_unstemmed Comparison of clinical pharmacology of voriconazole and posaconazole
title_sort comparison of clinical pharmacology of voriconazole and posaconazole
publisher Termedia Publishing House
series Contemporary Oncology
issn 1428-2526
1897-4309
publishDate 2016-12-01
description Despite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a quest for new antifungal drugs as well as for optimization of pharmacotherapy with already registered pharmaceutics. Voriconazole and posaconazole are broad-spectrum, new generation, triazole antifungal agents. The drugs are used in the pharmacotherapy of invasive aspergillosis, Candida and Fusarium infections. Voriconazole is also used in infections caused by Scedosporium . Posaconazole is used in the treatment of coccidioidomycosis and chromoblastomycosis. Besides some similarities, the two mentioned drugs also show differences in therapeutic indications, pharmacokinetics (mainly absorption and metabolism), frequency and severity of adverse drug reactions, drug–drug interactions and dosage. As both of the drugs are used in the treatment of invasive fungal infections in adults and children, detailed knowledge of the clinical pharmacology of antifungal agents is the main factor in pharmacotherapy optimization in treatment of fungal infections. The goal of the article is to present and compare the clinical pharmacology of voriconazole and posaconazole as well as to point out the indications and contraindications of using the drugs, determine factors influencing their pharmacotherapy, and provide information that might be helpful in the treatment of fungal infections.
topic voriconazole
posaconazole
clinical pharmacology
cytochrome P-450 enzyme system
drug monitoring
url https://www.termedia.pl/Comparison-of-clinical-pharmacology-of-voriconazole-and-posaconazole,3,28897,1,1.html
work_keys_str_mv AT beatamsienkiewicz comparisonofclinicalpharmacologyofvoriconazoleandposaconazole
AT łukaszłapinski comparisonofclinicalpharmacologyofvoriconazoleandposaconazole
AT annawielahojenska comparisonofclinicalpharmacologyofvoriconazoleandposaconazole
_version_ 1725714565085265920